Transition Therapeutics and Lilly's newest deal focuses on osteoarthritis
Transition Therapeutics Inc. (treatments for CNS, metabolic, and musculoskeletal conditions) has once again expanded its relationship with partner Eli Lilly & Co., this time getting exclusive rights to the Big Pharma’s preclinical osteoarthritis candidate TT601.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.